Polycyclo Ring System Patents (Class 514/753)
-
Patent number: 11826578Abstract: The present invention relates to a method for producing a nitrogen-based non-thermal atmospheric pressure plasma for treating damaged muscles or promoting regeneration of damaged muscles, and to a method for treating damaged muscle or promoting regeneration of damaged muscles using the atmospheric pressure plasma. The nitrogen-based non-thermal atmospheric pressure plasma according to the present invention can effectively induce muscle cell activation, migration of muscle cells to damaged sites, muscle cell proliferation, and muscle cell differentiation, without surgical operation or during a treatment procedure after surgical operation, and thus can be advantageously used as a novel therapeutic agent and therapeutic method against muscle damage and muscle damage-associated diseases.Type: GrantFiled: December 22, 2021Date of Patent: November 28, 2023Inventors: Chul Ho Kim, Sung Un Kang, Jae Won Choi
-
Publication number: 20150079111Abstract: Mechanisms for complications of renal failure and processes for treating the same are disclosed. They include contacting a biological fluid (e.g. blood) with a filter body, the filter body having immobilized thereon either a CD36 receptor or a CD36 receptor fragment or a SCARB1 receptor or a SCARB1 receptor fragment, the blood having a reduced quantity of oxidatively modified proteins after contacting the filter body. They also include administering an antagonist drug to a patient that blocks the binding activity of the RAGE receptor or the CD36 receptor or the SCARB1 receptor. Diagnostic methods are also provided.Type: ApplicationFiled: June 5, 2013Publication date: March 19, 2015Inventor: Jonas AXELSSON
-
Publication number: 20150030583Abstract: The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy.Type: ApplicationFiled: March 30, 2012Publication date: January 29, 2015Applicant: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Malcolm A.S. Moore, Server A. Ertem
-
Publication number: 20140243404Abstract: This disclosure is related to halonium compounds useful for cyclization of polyenes, alkenoic acids, and alkenyl alkyl ethers, and halogenation of aromatic compounds. The synthesis of such halonium compounds, compounds made using such halonium compounds, and synthesis of natural compounds, including decalins, using the halonium compounds is also disclosed.Type: ApplicationFiled: September 13, 2011Publication date: August 28, 2014Applicant: The Trustees of Columbia University in the City of New YorkInventors: Scott Alan Snyder, Daniel S. Treitler, Alexandria P. Brucks, Andreas Gollner, Maria I. Chiriac, Nathan E. Wright, Jason J. Pflueger, Steven P. Breazzano
-
Publication number: 20140199320Abstract: The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1?, IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of IL-1?, IL-1 receptor type 1, IL-1 receptor type 2, NLRP3, ASC and Caspase-1. Similarly, an interfering RNA or an antisense modulator of gene expression of IL-1?, I L-1? receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B are provided for the prevention or treatment of acne.Type: ApplicationFiled: July 11, 2012Publication date: July 17, 2014Applicant: UNIVERSITAT ZURICHInventors: Dragana Jankovic, Magdalena Kistowiska, Emmanuel Contassot, Lars E. French, Samuel Gehrke
-
Publication number: 20140148398Abstract: Compounds useful for the treatment of giardiasis are described.Type: ApplicationFiled: October 12, 2011Publication date: May 29, 2014Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
-
Publication number: 20120039888Abstract: The present invention relates to compositions and methods for treating inflammation-associated tissue damage, and particularly transfusion-associated, disorders, by inhibiting or reducing E-selectin mediated signal transduction pathways, such as E-selectin mediated activation of ?M?2.Type: ApplicationFiled: May 10, 2011Publication date: February 16, 2012Inventors: Paul Frenette, Andrés Hidalgo
-
Publication number: 20110027384Abstract: The present invention provides a photosensitising composition comprising a mixture of at least one oxygen carrier, at least one oxidising agent and at least one surfactant, and its uses. The ratio of the at least one oxygen carrier to the at least one oxidising agent to the at least one surfactant may be in the range of 50:40:10 to 80:19.8:0.2. The photosensitising composition may be used for treating and/or preventing conditions caused by microorganisms.Type: ApplicationFiled: April 6, 2009Publication date: February 3, 2011Applicant: National University of SingaporeInventors: Anil Kishen, Saji George
-
Patent number: 7618988Abstract: Compounds of formula I in which R has a meaning as indicated in claim 1, or one of their optical isomers or pharmaceutically acceptable salts, used for the treatment of extrapyramidal movement disorders and/or adverse effects in extrapyramidal movement disorders and/or for the treatment of extrapyramidal symptoms (EPS) induced by neuroleptics.Type: GrantFiled: August 12, 2002Date of Patent: November 17, 2009Assignee: Merck PatentgesellschaftInventors: Henning Böttcher, Ralf Devant, Maria Devant, legal representative, Gerd Bartoszyk, Hermann Russ, Frank Weber, Christoph Seyfried
-
Publication number: 20090149445Abstract: The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof. In addition, the present invention provides novel pharmaceutical compounds of Formula I, including the pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions which comprise as an active ingredient a compound of Formula I.Type: ApplicationFiled: July 15, 2008Publication date: June 11, 2009Inventors: Michael Joseph Coghlan, Jonathan Edward Green, Timothy Alan Grese, Prabhakar Kondaji Jadhav, Donald Paul Matthews, Mitchell Irvin Steinberg, Kevin Robert Fales, Michael Gregory Bell
-
Publication number: 20090105260Abstract: An IR spectroscopic technique provides methods for measuring the irritation potential of a formulation and to assess the ability of molecules to enhance the permeability of substances into and through skin using samples comprising stratum corneum. Molecules are screened for their performance as chemical penetration enhancers using a unique in silico procedure that may be applied iteratively in an attempt to generate molecules showing successively higher performance. Both the irritation potential and the ability of the molecule to enhance penetration are considered in the in silico approach. The invention provides specific molecules that may be used in topical or transdermal formulations to improve the delivery of actives. The structures of compounds of the invention include: Formulas (I), (II), (III), (IV), (V), (IV) and analogs thereof.Type: ApplicationFiled: January 17, 2006Publication date: April 23, 2009Inventors: Samir Mitragotri, Pankaj Karande, Amit K. Jain
-
Patent number: 7378449Abstract: An additive mixture useful as a flame retardant is described. The mixture is comprised of (i) a poly(bromophenyl)alkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups and (ii) a poly(bromophenyl)bromoalkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups, said poly(bromophenyl)bromoalkane being in an amount which is greater than 25 wt %, based on the total weight of the additive mixture. A facile process for making the poly(bromophenyl)bromoalkane is also described.Type: GrantFiled: October 23, 2006Date of Patent: May 27, 2008Assignee: Albemarle CorporationInventors: Raymond B. Dawson, Saadat Hussain
-
Publication number: 20070292493Abstract: The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel.Type: ApplicationFiled: June 15, 2006Publication date: December 20, 2007Inventor: Barbara T. Brierre
-
Patent number: 6967102Abstract: The present invention is directed to methods, pharmaceutical compositions and kits for modulating skeletal muscle precursor cell activation. Modulation is effected through the use of nitric oxide (NO), donors of NO, inhibitors of NO activity (NO inhibitor) or regulators of NO production, either locally or systemically. The invention further teaches the use of NO, an NO donor, an NO inhibitor or a regulator of NO production to modulate the effects of steroid hormone on skeletal muscle. The invention further provides a method for identifying a compound which effects a change in activation state of muscle precursor cells. A number of advantages is evident. By allowing skeletal muscle precursor cells to be manipulated directly, the invention enables specific treatments to regenerate and repair muscle.Type: GrantFiled: March 10, 2000Date of Patent: November 22, 2005Assignee: University of ManitobaInventor: Judy E. Anderson
-
Patent number: 6743825Abstract: An additive mixture useful as a flame retardant is described. The mixture is comprised of (i) a poly(bromophenyl)alkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups and (ii) a poly(bromophenyl)bromoalkane having in the molecule in the range of 13 to 60 carbon atoms and in the range of two to four aryl groups, said poly(bromophenyl)bromoalkane being in an amount which is greater than 25 wt %, based on the total weight of the additive mixture. A facile process for making the poly(bromophenyl)bromoalkane is also described.Type: GrantFiled: August 5, 2002Date of Patent: June 1, 2004Assignee: Albemarle CorporationInventors: Raymond B. Dawson, Saadat Hussain
-
Patent number: 6291534Abstract: In the literature, a correlation between the inhibition of 5-lipoxygenase and anti-inflammatory and immunomodulatory activity sufficient to effectively treat psoriasis, is known. It seems that, in particular, the excellent results can be obtained with lonapalene (6-chloro-2,3-dimethoxynaphthalendioldiacetate). However, the clinical use of lonapalene has not been successful most likely due to the significant number of side effects. With these considerations, after various studies, we have identified a molecule which we have patented with the name of endipalene, which seems to guarantee notable therapeutic results without side effects.Type: GrantFiled: May 25, 2000Date of Patent: September 18, 2001Inventor: Giorgio Endrici
-
Patent number: 6245782Abstract: The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or preventing an individual at risk for a vascular event, disease or disorder by administering a SSRI.Type: GrantFiled: May 17, 1999Date of Patent: June 12, 2001Assignee: Heartdrug Research L.L.C.Inventors: Victor L. Serebruany, Paul A. Gurbel, Christopher M. O'Connor
-
Patent number: 5859068Abstract: A method for the acceleration of tissue growth using continuous fluorocarbon liquid-based positive pressure is disclosed, whereby significant increase in tissue growth is achieved.Type: GrantFiled: February 24, 1995Date of Patent: January 12, 1999Assignee: Children's Medical Center CorporationInventor: Jay M. Wilson
-
Patent number: 5856272Abstract: A novel algaecide composition and method of removing algae from a variety of surfaces, in particular a composition comprising at least one terpene and at least one algaecidal agent, is disclosed.Type: GrantFiled: November 13, 1995Date of Patent: January 5, 1999Inventor: Joe S. Wilkins, Jr.
-
Patent number: 5834521Abstract: Tetracyclic compounds having the following structure are described: ##STR1## wherein R.sub.1 -R.sub.10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovulatory effects and potent steroid receptor binding. The compounds have therapeutic utility in reproductive applications such as fertility control, labor induction, ovulation induction and spermatogenesis. Methods for preparing the tetracyclic compounds from substituted indanones are also described.Type: GrantFiled: August 5, 1996Date of Patent: November 10, 1998Assignee: Ortho Pharmaceutical CorporationInventors: John H. Dodd, Lisa A. Dixon, James L. Bullington, Charles F. Schwender
-
Patent number: 5824703Abstract: A method of assisting a mammal having a lung disorder to breathe ambient gas normally, i.e., without the assistance of a ventilator. The method includes providing an animal having a lung disorder, such as surfactant deficiency, stiff lung, or hyperinflated lung syndrome, and instilling a minimum effective dose of a perfluorochemical liquid or emulsion through the trachea for coating the alveolar sacs of a lung of the mammal. The preferred perfluorochemicals have a very low vapor pressure to avoid inducing hyperinflated lung syndrome and are supplied in a minimum effective dosage sufficient to coat the inner lung surfaces. The perfluorochemicals are permeable to the ambient gas and reside substantially permanently within the alveolar sacs without inducing hyperinflated lung syndrome. The liquid is instilled in an amount sufficient to enable the animal to breathe the ambient gas normally with O.sub.2 /CO.sub.2 blood gas exchange. Effective coating of the lungs with a small (generally <0.Type: GrantFiled: December 27, 1996Date of Patent: October 20, 1998Assignee: Synthetic Blood International, Inc.Inventor: Leland C. Clark, Jr.
-
Patent number: 5543298Abstract: The method for assaying the SOD (super oxide dismutase) activity in liquid medium is based on the activation of self-oxidization, by SOD activity, of a reactive agent having the general formula (I) wherein either n is 1 or 2, R.sup.1 is --OR.sup.4 or --NR.sup.5 R.sup.6 ; R.sup.2 is H, --OR.sup.4, alkyl (1-6C), --CH.sub.2 -- or --CH.sub.2 --CH.sub.2 --, to form a ring by binding to the phenyl substituent, at meta with respect to R.sup.1 ; and R.sup.3 is H, alkyl (1-6C) or --OR.sup.4 (if R.sup.2 is different from --OR.sup.4); with R.sup.4 being H or alkyl (1-6C); R.sup.5 being H, alkyl (1-6C), --CH.sub.2 COOH, --C.sub.6 H.sub.5 COOH or --C.sub.6 H.sub.5 SO.sub.3 H; and R.sup.6 is H, alkyl (1-6C) or --CH.sub.2 COOH; or n is 1, R.sup.1 is --OR.sup.4, R.sup.2 is --CH.sub.2 --O--, in order to form a ring by bonding of O with the phenyl substituent, at meta with respect to R.sup.1 ; and R.sup.3 is H or --OR.sup.4.Type: GrantFiled: June 6, 1994Date of Patent: August 6, 1996Assignee: Oxis International S.A.Inventors: Jinzhu Xu, Jean-Claude Y. Yadan, Marc E. Moutet, Jean R. Chaudiere
-
Patent number: 4803067Abstract: Compositions for cosmetics and dermatology comprising a perfluoropolyether liquid dispersed in an oil/water or water/oil emulsion, or in a solid phase suited to form a gel, suspended in an organic liquid phase.Type: GrantFiled: March 26, 1986Date of Patent: February 7, 1989Assignee: Ausimont S.p.A.Inventors: Fabio Brunetta, Stefano Bader, Giovanni Pantini
-
Patent number: 4769241Abstract: Perfluorocarbon emulsion formulations are oxygenated prior to use by means of a portable oxygenation system. The blood substitute is in a closed container or bag. An oxygen-containing gas is introduced into the bag from a separate container. The bag is continuously agitated for a sufficient time to increase the pO.sub.2 of the perfluorocarbon emulsion formulations to a desired pressure, e.g., to at least 600 mmHg. In one embodiment, the system used for oxygenation of the perfluorocarbon emulsion formulations comprises a small tank for gas having an inlet port and an outlet port fitted with shut-off valves. The outlet port is adapted to be connected to a filter which, in turn, is adapted to be connected to the inlet port of a three-way valve. The primary outlet of the three-way valve is adapted to mount a hypodermic needle which is adapted to be pushed through a rubber septum in a port of the bag to communicate with the interior of the bag.Type: GrantFiled: September 23, 1986Date of Patent: September 6, 1988Assignee: Alpha Therapeutic CorporationInventors: Charles M. Heldebrant, Kim C. Crowe, George R. Groveman, Charles H. Davis, Jr.
-
Patent number: RE44704Abstract: The present invention is based on the discovery that the administration of at least one immunoconjugate and at least one chemotherapeutic agent provides an unexpectedly superior treatment for cancer. The present invention is directed to compositions comprising at least one immunoconjugate and at least one chemotherapeutic agent and to methods of treating cancer using at least one immunoconjugate and at least one chemotherapeutic agent. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one chemotherapeutic agent and at least one immunoconjugate.Type: GrantFiled: September 13, 2012Date of Patent: January 14, 2014Assignee: Immunogen Inc.Inventors: Ravi V. J. Chari, Walter A. Blättler